Lexeo Therapeutics, Inc. Common Stock
$4.20
$0.02 (+0.48%)
$4.06Day Range$4.22
Key Statistics
Market Cap
$344.59M
Shares Outstanding
82.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 3, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$4.16
Day High
$4.22
Day Low
$4.06
Volume
2.29M
VWAP
$4.19
Prev Close
$4.18
Transactions
--
Acc. Volume
--
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283659 employees345 PARK AVENUE SOUTH, NEW YORK, NY, 10010(212) 547-9879IPO Nov 3, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001907108
- Composite FIGI
- BBG00YB1C8M5
- Share Class FIGI
- BBG00YB1C8N4
- Ticker Root
- LXEO
- SIC Code
- 2836
About Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock
Lexeo Therapeutics, Inc. Common Stock (LXEO) closed the 2026-09-18 session at $4.20, up 0.48% versus the previous close (+0.02). The stock opened at $4.16 and traded between $4.06 and $4.22 during that session. Session trading volume was 2.3M shares. The volume-weighted average price (VWAP) is $4.19.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Lexeo Therapeutics, Inc. Common Stock has a market capitalization of $344.6 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. LXEO is listed on the XNAS exchange. The company employs approximately 59 people. Lexeo Therapeutics, Inc. Common Stock is headquartered in NEW YORK, NY. The recorded listing date is 2023-11-03.
On this page you can find market LXEO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.